Functional analysis of apoptosis induction in acute myeloid leukaemia-relevance of karyotype and clinical treatment response

British Journal of Haematology

Volumn 126, Issue 3, 2004, Pages 338-347

  Braess, Jan ^a   Schneiderat, Peter ^a   Schoch, Claudia ^a   Fiegl, Michael ^a   Lorenz, Isolde ^a   Hiddemann, Wolfgang ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Acute myeloid leukaemia; Apoptosis; Blebbing; Caspase; Resistance

Indexed keywords

ANTIINFECTIVE AGENT; CASPASE 3; CYTARABINE; CYTOTOXIC AGENT; ETOPOSIDE; FAS LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; ENZYME ACTIVITY; FUNCTIONAL ASSESSMENT; HUMAN; HUMAN CELL; HYPOTHESIS; KARYOTYPE; PRIORITY JOURNAL;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CASPASE 3; CASPASES; CYTARABINE; ENZYME ACTIVATION; ETOPOSIDE; FAS LIGAND PROTEIN; FEMALE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NUCLEIC ACID SYNTHESIS INHIBITORS; TREATMENT OUTCOME;

EID: 3442888069     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.05039.x     Document Type: Article

References (44)

1. Anonymous (1997) World medical association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Journal of the American Medical Association, 277, 925-926.
2. Appelbaum, F.R. & Kopecky, K.J. (1997) Long-term survival after chemotherapy for acute myeloid leukemia: the experience of the Southwest Oncology Group. Cancer, 80, 2199-2204.
3. Bloomfield, C.D., Shuma, C., Regal, L., Philip, P.P., Hossfeld, D.K., Hagemeijer, A.M., Garson, O.M., Peterson, B.A., Sakurai, M., Alimena, G., Berger, R., Rowley, J.D., Ruutu, T., Mitelman, F., Dewald, G.W. & Swansbury, J. (1997) Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer, 80, 2191-2198.
4. Bloomfield, C.D., Lawrence, D., Byrd, J.C., Carroll, A., Pettenati, M.J., Tantravahi, R., Patil, S.R., Davey, F.R., Berg, D.T., Schiffer, C.A., Arthur, D.C. & Mayer, R.J. (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Research, 58, 4173-4179.
5. Boiron, J.M., Lerner, D., Pigneux, A., Faberes, C., Bordessoule, D., Turlure, P., Cony-Makhoul, P., Hau, F., Dazey, B., Agape, P., Reiffers, I. & Marit, G. (2001) Allogeneic transplantation for patients with advanced acute leukemia: a single center retrospective study of 92 patients. Leukemia and Lymphoma, 41, 285-296.
6. Borg, A.G., Burgess, R., Green, L.M., Scheper, R.J. & Liu Yin, J.A. (2000) P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells. British Journal of Haematology, 108, 48-54.
7. Braess, J., Voss, S., Jahns-Streubel, G., Schoch, C., Haferlach, T., Kern, W., Keye, S., Schleyer, E. & Hiddemann, W. (2000) The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity. British Journal of Haematology, 110, 170-179.
8. Braess, J., Jahns-Streubel, G., Schoch, C., Haase, D., Haferlach, T., Fiegl, M., Voss, S., Kern, W., Schleyer, E. & Hiddemann, W. (2001) Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia. British Journal of Haematology, 113, 975-982.
9. Buchner, T., Hiddemann, W., Wormann, B., Loffler, H., Gassmann, W., Haferlach, T., Fonatsch, C., Haase, D., Schoch, C., Hossfeld, D., Lengfelder, E., Aul, C., Heyll, A., Maschmeyer, G., Ludwig, W.D., Sauerland, M.C. & Heinecke, A. (1999) Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood, 93, 4116-4124.
10. Burnett, A.K., Goldstone, A.H., Stevens, R.M., Hann, I.M., Rees, J.K., Gray, R.G. & Wheatley, K. (1998) Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet, 351, 700-708.
11. Dash, A. & Gilliland, D.G. (2001) Molecular genetics of acute myeloid leukaemia. Best Practice and Research. Clinical Haematology, 14, 49-64.
12. Estey, E.H. (2000) Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia, 14, 476-479.
13. Fonatsch, C., Schaadt, M., Kirchner, H. & Diehl, V. (1980) A possible correlation between the degree of karyotype aberrations and the rate of sister chromatid exchanges in lymphoma lines. International Journal of Cancer, 26, 749-756.
14. Grigg, A.P., Szer, J., Beresford, J., Dodds, A., Bradstock, K., Durrant, S., Schwarer, A.P., Hughes, T., Herrmann, R., Gibson, J., Arthur, C. & Matthews, J. (1999) Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. British Journal of Haematology, 107, 409-418.
15. van den Heuvel-Eibrink, M.M., Wiemer, E.A., de Boevere, M.J., Slater, R.M., Smit, E.M., van Noesel, M.M., van der Holt, B., Schoester, M., Pieters, R. & Sonneveld, P. (2001a) MDR1 expression in poor-risk acute myeloid leukemia with partial or complete monosomy 7. Leukemia, 15, 398-405.
16. van den Heuvel-Eibrink, M.M., Wiemer, E.A., de Boevere, M.J., van der Holt, B., Vossebeld, P.J., Pieters, R. & Sonneveld, P. (2001b) MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood, 97, 3605-3611.
17. Kamikubo, K.H., Ogata, K., An, E. & Dan, K. (2000) Low proportion of GO-phase cells during induction chemotherapy correlates with subsequent remission in acute myeloid leukemia. International Journal of Hematology, 71, 249-255.
18. Kelly, L.M., Liu, Q., Kutok, J.L., Williams, I.R., Boulton, C.L. & Gilliland, D.G. (2002) FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood, 99, 310-318.
19. Kern, W., Schleyer, E., Unterhalt, M., Wormann, B., Buchner, T. & Hiddemann, W. (1997) High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study. Cancer, 79, 59-68.
20. Kern, W., Aul, C., Maschmeyer, G., Schonrock-Nabulsi, R., Ludwig, W.D., Bartholomaus, A., Bettelheim, P., Wormann, B., Buchner, T. & Hiddemann, W. (1998) Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Leukemia, 12, 1049-1055.
21. Kern, W., Schleyer, E., Braess, J., Wittmer, E., Ohnesorge, J., Unterhalt, M., Wormann, B., Buchner, T. & Hiddemann, W. (2001) Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias. Annals of Hematology, 80, 334-339.
22. Kessel, M., Gieseler, F. & Woodcock, B.G. (1999) Influence of serum protein binding on the uptake and retention of idarubicin by sensitive and multidrug resistant human leukemic cells. European Journal of Clinical Pharmacology, 55, 369-373.
23. Kravtsov, V.D., Greer, J.P., Whitlock, J.A. & Koury, M.J. (1998) Use of the microculture kinetic assay of apoptosis to determine chemosensitivities of leukemias. Blood, 92, 968-980.
24. Kravtsov, V.D., Daniel, T.O. & Koury, M.J. (1999) Comparative analysis of different methodological approaches to the in vitro study of drug-induced apoptosis. American Journal of Pathology, 155, 1327-1339.
25. Landowski, T.H., Moscinski, L., Burke, R., Buyuksal, I., Painter, J.S., Goldstein, S. & Dalton, W.S. (2001) CD95 antigen mutations in hematopoietic malignancies. Leukemia and Lymphoma, 42, 835-846.
26. Legrand, O., Simonin, G., Beauchamp-Nicoud, A., Zittoun, R. & Marie, J.P. (1999) Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood, 94, 1046-1056.
27. Lewis, N.R., Pallis, M. & Russell, N.H. (2000) Fas receptor-Fas ligand system is independent of both CD34 status and chemosensitivity in acute myeloid leukemia. Experimental Hematology, 28, 535-542.
28. Litman, T., Druley, T.E., Stein, W.D. & Bates, S.E. (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cellular and Molecular Life Science, 58, 931-959.
29. Maeno, E., Ishizaki, Y., Kanaseki, T., Hazama, A. & Okada, Y. (2000) Normotonic cell shrinkage because of disordered volume regulation is an early prerequisite to apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 97, 9487-9492.
30. Marcucci, G., Caligiuri, M.A. & Bloomfield, C.D. (2000) Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. Cancer Investigation, 18, 768-780.
31. Mayer, R.J., Davis, R.B., Schiffer, C.A., Berg, D.T., Powell, B.L., Schulman, P., Omura, G.A., Moore, J.O., McIntyre, O.R. & Frei, E., 3rd, 1994. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. New England Journal of Medicine, 331, 896-903.
32. Michallet, M., Thomas, X., Vernant, J.P., Kuentz, M., Socie, G., Esperou-Bourdeau, H., Milpied, N., Blaise, D., Rio, B., Reiffers, J., Jouet, J.P., Cahn, J.Y., Bourhis, J.H., Lioure, B., Leporrier, M., Sotto, J.J., Souillet, G., Sutton, L., Bordigoni, P., Dreyfus, F., Tilly, H., Gratecos, N., Attal, M., Leprise, P.Y., Demeocq, F., Michel, G., Buzyn, A., Delmas-Marsalet, B., Bernaudin, F., Ifrah, N., Sadoun, A., Guyotat, D., Cavazzana-Cavo, M., Caillot, D., De Revel, T., Vannier, J.P., Baruchel, A., Fegueux, N., Tanguy, M.L., Thiebaut, A., Belhabri, A. & Archimbaud, E. (2000) Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplantation, 26, 1157-1163.
33. Mrozek, K., Heinonen, K. & Bloomfield, C.D. (2000) Prognostic value of cytogenetic findings in adults with acute myeloid leukemia. International Journal of Hematology, 72, 261-271.
34. Munker, R., Lubbert, M., Yonehara, S., Tuchnitz, A., Mertelsmann, R. & Wilmanns, W. (1995) Expression of the Fas antigen on primary human leukemia cells. Annals of Hematology, 70, 15-17.
35. Norgaard, J.M., Langkjer, S.T., Palshof, T., Clausen, N., Pedersen, B. & Hokland, P. (1996) Relation of blast cell survival and proliferation to chemotherapy resistance in AML. British Journal of Haematology, 93, 888-897.
36. Nussler, V., Pelka-Fleischer, R., Zwierzina, H., Nerl, C., Beckert, B., Gieseler, F., Diem, H., Ledderose, G., Gullis, E., Sauer, H. & Wilmanns, W. (1996) P-glycoprotein expression in patients with acute leukaemia - clinical relevance. Leukemia, 10(Suppl. 3), S23-S31.
37. Pandolfi, P.P. (2001) In vivo analysis of the molecular genetics of acute promyelocytic leukemia. Oncogene, 20, 5726-5735.
38. Rozenfeld-Granot, G., Toren, A., Amariglio, N., Brok-Simoni, F. & Rechavi, G. (2001) Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies. Experimental Hematology, 29, 228-233.
39. Stollmann, B., Fonatsch, C. & Havers, W. (1985) Persistent Epstein-Barr virus infection associated with monosomy 7 or chromosome 3 abnormality in childhood myeloproliferative disorders. British Journal of Haematology, 60, 183-196.
40. Svingen, P.A., Karp, J.E., Krajewski, S., Mesner, Jr, P.W., Gore, S.D., Burke, P.J., Reed, J.C., Lazebnik, Y.A. & Kaufmann, S.H. (2000) Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. Blood, 96, 3922-3931.
41. Thomas, X., Fenaux, P., Dombret, H., Delair, S., Dreyfus, F., Tilly, H., Vekhoff, A., Cony-Makhoul, P., Leblond, V., Troussard, X., Cordonnier, C., de Revel, T., Simon, M., Nicolini, F., Stoppa, A.M., Janvier, M., Bordessoule, D., Rousselot, P., Ffrench, M., Marie, J.P. & Archimbaud, E. (1999) Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). Leukemia, 13, 1214-1220.
42. de Thonel, A., Bettaieb, A., Jean, C., Laurent, G. & Quillet-Mary, A. (2001) Role of protein kinase C zeta isoform in Fas resistance of immature myeloid KG1a leukemic cells. Blood, 98, 3770-3777.
43. Wuchter, C., Karawajew, L., Ruppert, V., Buchner, T., Schoch, C., Haferlach, T., Ratei, R., Dorken, B. & Ludwig, W.D. (1999) Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P- glycoprotein function, maturation stage, and cytogenetics. Leukemia, 13, 1943-1953.
44. Wuchter, C., Krappmann, D., Cai, Z., Ruppert, V., Scheidereit, C., Dorken, B., Ludwig, W.D. & Karawajew, L. (2001) In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity. Leukemia, 15, 921-928.